See more : Sai Silks (Kalamandir) Limited (KALAMANDIR.NS) Income Statement Analysis – Financial Results
Complete financial analysis of United Therapeutics Corporation (UTHR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of United Therapeutics Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- Lloyds Banking Group plc (LLD.DE) Income Statement Analysis – Financial Results
- Safe Pro Group Inc. Common Stock (SPAI) Income Statement Analysis – Financial Results
- Independent Bank Corp. (INDB) Income Statement Analysis – Financial Results
- BioVaxys Technology Corp. (BVAXF) Income Statement Analysis – Financial Results
- Brookfield Office Properties Inc (BPO-PE.TO) Income Statement Analysis – Financial Results
United Therapeutics Corporation (UTHR)
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.33B | 1.94B | 1.69B | 1.48B | 1.45B | 1.63B | 1.73B | 1.60B | 1.47B | 1.29B | 1.12B | 916.08M | 743.18M | 603.83M | 369.85M | 281.50M | 210.94M | 159.63M | 115.92M | 73.59M | 53.34M | 30.12M | 5.73M | 2.05M | 400.00K | 100.00K |
| Cost of Revenue | 257.50M | 146.70M | 122.50M | 108.10M | 117.60M | 198.70M | 105.70M | 72.70M | 69.04M | 125.88M | 131.13M | 119.30M | 88.90M | 73.47M | 45.32M | 30.07M | 22.26M | 17.03M | 12.32M | 8.25M | 6.78M | 5.46M | 3.14M | 1.71M | 1.40M | 0.00 |
| Gross Profit | 2.07B | 1.79B | 1.56B | 1.38B | 1.33B | 1.43B | 1.62B | 1.53B | 1.40B | 1.16B | 985.86M | 796.78M | 654.28M | 530.37M | 324.53M | 251.43M | 188.68M | 142.60M | 103.60M | 65.34M | 46.56M | 24.66M | 2.59M | 343.47K | -1.00M | 100.00K |
| Gross Profit Ratio | 88.94% | 92.42% | 92.73% | 92.71% | 91.88% | 87.79% | 93.87% | 95.45% | 95.29% | 90.23% | 88.26% | 86.98% | 88.04% | 87.83% | 87.75% | 89.32% | 89.45% | 89.33% | 89.38% | 88.79% | 87.28% | 81.89% | 45.27% | 16.76% | -250.00% | 100.00% |
| Research & Development | 408.00M | 322.90M | 540.10M | 357.70M | 1.18B | 357.90M | 264.60M | 147.60M | 245.10M | 242.55M | 299.35M | 173.39M | 180.02M | 166.76M | 122.19M | 239.18M | 83.35M | 57.57M | 36.05M | 30.60M | 35.42M | 26.78M | 32.59M | 70.19M | 30.70M | 11.00M |
| General & Administrative | 395.30M | 416.20M | 402.60M | 369.00M | 275.50M | 206.70M | 265.80M | 232.20M | 358.32M | 299.29M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.44M | 16.94M | 11.74M | 5.00M | 0.00 |
| Selling & Marketing | 81.80M | 70.80M | 64.40M | 54.90M | 60.70M | 59.10M | 64.30M | 84.60M | 94.30M | 82.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.45M | 3.38B | 0.00 | 0.00 | 0.00 |
| SG&A | 477.10M | 487.00M | 467.00M | 423.90M | 336.20M | 265.80M | 330.10M | 316.80M | 452.61M | 381.29M | 394.01M | 201.75M | 156.48M | 199.60M | 176.34M | 94.31M | 99.03M | 54.03M | 24.66M | 21.53M | 22.67M | 15.89M | 16.94M | 11.74M | 5.00M | 2.40M |
| Other Expenses | 0.00 | -40.20M | 42.20M | 49.30M | 22.60M | -7.70M | 13.20M | 2.40M | 157.00K | 3.97M | 635.00K | 31.87M | 156.48M | 199.60M | 176.34M | 94.31M | 99.03M | 56.05M | 24.66M | 21.53M | 22.67M | 15.89M | 0.00 | -79.74K | -1.30M | 2.40M |
| Operating Expenses | 885.10M | 809.90M | 1.01B | 781.60M | 1.52B | 623.70M | 594.70M | 464.40M | 697.71M | 623.84M | 693.36M | 375.13M | 336.50M | 366.36M | 298.53M | 333.49M | 182.38M | 113.62M | 60.71M | 52.13M | 58.08M | 42.67M | 49.53M | 81.84M | 34.40M | 13.40M |
| Cost & Expenses | 1.14B | 956.60M | 1.13B | 889.70M | 1.64B | 822.40M | 700.40M | 537.10M | 766.75M | 749.72M | 824.49M | 494.43M | 425.40M | 439.83M | 343.85M | 363.55M | 204.64M | 130.65M | 73.02M | 60.38M | 64.87M | 48.12M | 52.67M | 83.55M | 35.80M | 13.40M |
| Interest Income | 162.70M | 45.20M | 16.70M | 28.60M | 44.20M | 28.60M | 10.90M | 3.50M | 0.00 | 0.00 | 3.83M | 3.94M | 3.45M | 2.94M | 5.15M | 11.03M | 13.60M | 10.70M | 5.36M | 2.99M | 2.44M | 4.95M | 10.02M | 10.69M | 0.00 | 0.00 |
| Interest Expense | 59.30M | 32.40M | 18.60M | 23.50M | 44.20M | 13.90M | 9.00M | 3.90M | 4.74M | 17.59M | 18.06M | 16.64M | 21.37M | 19.71M | 12.88M | 16.00K | 2.18M | 482.00K | 29.00K | 4.00K | 112.00K | 117.00K | 172.72K | 120.04K | 0.00 | 0.00 |
| Depreciation & Amortization | 53.20M | 51.30M | 49.90M | 49.90M | 45.90M | 35.90M | 31.00M | 31.60M | 32.92M | 32.25M | 31.26M | 27.15M | 20.54M | 17.92M | 11.39M | 4.54M | 957.00K | 1.46M | 2.41M | 2.28M | 2.33M | 3.14M | 3.51M | -79.74K | -1.30M | -500.00K |
| EBITDA | 1.39B | 1.04B | 736.80M | 646.30M | -74.90M | 838.40M | 1.05B | 1.09B | 1.08B | 575.02M | 323.76M | 484.46M | 341.02M | 185.47M | 43.04M | -67.75M | 22.19M | 28.98M | 50.09M | 17.83M | -9.20M | -14.87M | -43.42M | -81.58M | -36.66M | -13.80M |
| EBITDA Ratio | 59.58% | 50.85% | 36.48% | 45.27% | -8.34% | 50.76% | 60.17% | 66.56% | 47.70% | 42.12% | 26.59% | 52.88% | 43.21% | 27.62% | 8.38% | -25.31% | 3.83% | 19.59% | 39.04% | 20.98% | -17.60% | -15.25% | -754.18% | -3,752.55% | -9,200.00% | -13,800.00% |
| Operating Income | 1.18B | 979.70M | 555.90M | 593.60M | -187.60M | 805.40M | 814.90M | 1.06B | 699.02M | 538.80M | 292.50M | 421.65M | 317.78M | 164.01M | 26.00M | -82.06M | 6.30M | 28.98M | 42.89M | 13.21M | -11.53M | -18.00M | -46.94M | -81.50M | -35.40M | -13.30M |
| Operating Income Ratio | 50.91% | 50.60% | 32.98% | 40.02% | -12.95% | 49.48% | 47.23% | 66.41% | 47.69% | 41.82% | 26.19% | 46.03% | 42.76% | 27.16% | 7.03% | -29.15% | 2.99% | 18.16% | 37.00% | 17.95% | -21.61% | -59.77% | -818.93% | -3,977.08% | -8,850.00% | -13,300.00% |
| Total Other Income/Expenses | 89.40M | -29.10M | 38.00M | 45.30M | 22.60M | -46.50M | -45.40M | -1.50M | 345.42M | -13.60M | -13.60M | 19.03M | -18.67M | -16.17M | -7.23M | 9.76M | 10.28M | 10.93M | 4.63M | 2.24M | 1.56M | -5.65M | 9.65M | -4.68M | 63.50K | 546.20K |
| Income Before Tax | 1.27B | 950.60M | 593.90M | 638.90M | -165.00M | 758.90M | 769.50M | 1.06B | 1.04B | 525.18M | 278.90M | 440.67M | 299.12M | 147.84M | 18.77M | -72.30M | 16.58M | 39.91M | 47.52M | 15.45M | -9.97M | -23.65M | -37.29M | -86.18M | -35.30M | -12.80M |
| Income Before Tax Ratio | 54.75% | 49.09% | 35.24% | 43.07% | -11.39% | 46.62% | 44.60% | 66.31% | 71.26% | 40.76% | 24.97% | 48.10% | 40.25% | 24.48% | 5.07% | -25.68% | 7.86% | 25.00% | 41.00% | 20.99% | -18.69% | -78.52% | -650.55% | -4,205.51% | -8,825.00% | -12,800.00% |
| Income Tax Expense | 289.50M | 223.30M | 118.10M | 124.10M | -60.50M | 169.70M | 351.60M | 346.50M | 392.80M | 185.11M | 104.34M | 136.23M | 81.87M | 41.92M | -695.00K | -29.51M | -3.28M | -34.06M | -17.49M | -3.03M | -2.51M | 5.44M | -9.65M | -5.89M | -1.90M | 0.00 |
| Net Income | 984.80M | 727.30M | 475.80M | 514.80M | -104.50M | 589.20M | 417.90M | 713.70M | 651.64M | 340.07M | 174.56M | 304.44M | 217.87M | 105.92M | 19.46M | -42.79M | 19.86M | 73.97M | 65.02M | 15.45M | -9.97M | -23.65M | -37.29M | -75.61M | -33.50M | -12.80M |
| Net Income Ratio | 42.31% | 37.56% | 28.23% | 34.71% | -7.21% | 36.20% | 24.22% | 44.64% | 44.46% | 26.39% | 15.63% | 33.23% | 29.32% | 17.54% | 5.26% | -15.20% | 9.41% | 46.33% | 56.09% | 20.99% | -18.69% | -78.52% | -650.55% | -3,689.55% | -8,375.00% | -12,800.00% |
| EPS | 21.04 | 15.98 | 10.60 | 11.65 | -2.39 | 13.54 | 9.50 | 16.29 | 14.17 | 7.06 | 3.49 | 5.84 | 3.81 | 1.89 | 0.37 | -0.93 | 0.47 | 1.61 | 1.43 | 0.36 | -0.24 | -0.57 | -0.92 | -1.97 | -1.26 | -0.77 |
| EPS Diluted | 19.81 | 15.00 | 10.06 | 11.54 | -2.39 | 13.39 | 9.31 | 15.25 | 12.72 | 6.28 | 3.28 | 5.71 | 3.67 | 1.78 | 0.35 | -0.93 | 0.44 | 1.53 | 1.29 | 0.33 | -0.24 | -0.57 | -0.92 | -1.97 | -1.26 | -0.77 |
| Weighted Avg Shares Out | 46.80M | 45.50M | 44.90M | 44.20M | 43.80M | 43.50M | 44.00M | 43.80M | 46.00M | 48.18M | 50.08M | 52.09M | 57.16M | 56.14M | 53.31M | 45.80M | 42.45M | 46.02M | 45.65M | 43.45M | 42.27M | 41.29M | 40.57M | 38.47M | 26.69M | 16.64M |
| Weighted Avg Shares Out (Dil) | 49.70M | 48.50M | 47.30M | 44.60M | 43.80M | 44.00M | 44.90M | 46.80M | 51.22M | 54.16M | 53.23M | 53.28M | 59.40M | 59.52M | 56.13M | 45.80M | 44.90M | 48.28M | 50.41M | 46.70M | 42.27M | 41.29M | 40.57M | 38.47M | 26.69M | 16.64M |
United Therapeutics Corporation (UTHR) Hit a 52 Week High, Can the Run Continue?
Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term
Why United Therapeutics (UTHR) is a Top Momentum Stock for the Long-Term
United Therapeutics (UTHR) Completes Enrolment in IPF Study
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?
3 Undervalued Stocks on Track to Double (or More) by 2028
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
Big Money Elevating United Therapeutics
Here's Why United Therapeutics (UTHR) is a Strong Value Stock
Source: https://incomestatements.info
Category: Stock Reports